Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Daniel Einhorn

Endocrinology, Diabetes & Metabolism La Jolla, CA Medical Doctor

NPI 1275525776 CMS profile 329814

9850 Genesee Ave, Suite 415, La Jolla, CA 92037

Open in the dashboard

General payments

$578,406

548 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Daniel Einhorn of La Jolla, CA is reported in the CMS Open Payments database as having received $578,406 across 548 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Endocrinology, Diabetes & Metabolism profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,218 3
2024 General $99 2
2023 General $4,944 11
2022 General $83,625 29
2021 General $215,103 164
2020 General $143,060 156
2019 General $130,357 183

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Daniel Einhorn
  • Endocrinology, Diabetes & Metabolism median
  • Middle half of Endocrinology, Diabetes & Metabolism
  • National median

In program year 2025, general payments to Daniel Einhorn were reported at $1,218. Among 5,868 Endocrinology, Diabetes & Metabolism profiles paid that year, the median was $507 and the middle half received between $135 and $1,838.

Show as a table
Year Daniel Einhorn Endocrinology, Diabetes & Metabolism median Middle half National median
2019 $130,357 $494 $123–$2,253 $163
2020 $143,060 $335 $85–$1,841 $114
2021 $215,103 $398 $88–$1,981 $132
2022 $83,625 $364 $88–$1,568 $149
2023 $4,944 $420 $113–$1,614 $160
2024 $99 $440 $121–$1,646 $164
2025 $1,218 $507 $135–$1,838 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $170,701 128 payments
  2. Lilly USA, LLC $139,080 175 payments
  3. Abbott Laboratories $83,869 66 payments
  4. Intuity Medical Inc $57,812 7 payments
  5. Corcept Therapeutics $45,193 26 payments
  6. Janssen Pharmaceuticals, Inc $23,608 69 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $15,492 19 payments
  8. Sanofi-Aventis U.S. LLC $14,565 16 payments
  9. Eli Lilly and Company $5,250 2 payments
  10. AstraZeneca Pharmaceuticals LP $5,070 6 payments
  11. Other $17,766 34 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $386,132 218 payments
  2. Consulting Fee $83,803 26 payments
  3. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $50,988 34 payments
  4. Compensation for serving as faculty or as a speaker for a medical education program $30,750 23 payments
  5. Travel and Lodging $20,384 92 payments
  6. Food and Beverage $6,285 153 payments
  7. Gift $59 1 payment
  8. Education $6 1 payment
Products named General payments · program years 2019–2025
  1. RYBELSUS $82,539 62 payments
  2. BAQSIMI $60,843 61 payments
  3. JARDIANCE Diabetes $58,365 48 payments
  4. Pogo Automatic Blood Glucose Monitoring System $57,812 7 payments
  5. FreeStyle Libre Pro Diabetes Care $52,115 37 payments
  6. Korlym $45,193 26 payments
  7. Ozempic $41,103 34 payments
  8. FreeStyle Libre Pro Diabetes Care $27,994 22 payments
  9. INVOKANA $23,889 76 payments
  10. JARDIANCE Diabetes $15,444 18 payments
  11. Other $77,246 117 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

548 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Endocrinology, Diabetes & Metabolism in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record